Inhibikase Therapeutics
(NASDAQ) IKT
Inhibikase Therapeutics Financials at a Glance
Market Cap
$220.50M
Revenue (TTM)
$0.00
Net Income (TTM)
$48.26M
EPS (TTM)
$-0.49
P/E Ratio
-3.39
Dividend
$0.00
Beta (Volatility)
0.90 (Low)
Dividend
$0.00
Beta (Volatility)
0.90 (Low)
Price
$1.68
Volume
598
Open
$1.79
Price
$1.68
Volume
598
Open
$1.79
Previous Close
$1.67
Daily Range
$1.63 - $1.80
52-Week Range
$1.33 - $2.37
Dividend
$0.00
Beta (Volatility)
0.90 (Low)
Price
$1.68
Volume
598
Open
$1.79
Previous Close
$1.67
Daily Range
$1.63 - $1.80
52-Week Range
$1.33 - $2.37
IKT News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Inhibikase Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
35
CEO
Mark T. Iwicki, MBA
Website
www.inhibikase.comHeadquarters
Atlanta, GA 30339, US
IKT Financials
Key Financial Metrics (TTM)
Gross Margin
0%
Operating Margin
0%
Net Income Margin
0%
Return on Equity
-36%
Return on Capital
-27%
Return on Assets
-27%
Earnings Yield
-29.50%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$220.50M
Shares Outstanding
132.03M
Volume
598
Short Interest
0.00%
Avg. Volume
1.97M
Financials (TTM)
Gross Profit
$60.50K
Operating Income
$45.95M
EBITDA
$45.89M
Operating Cash Flow
$27.79M
Capital Expenditure
$13.40K
Free Cash Flow
$27.79M
Cash & ST Invst.
$178.76M
Total Debt
$0.00
Inhibikase Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
$36.81K
-460.5%
Gross Margin
0.00%
N/A
Market Cap
$220.50M
N/A
Market Cap/Employee
$14.70M
N/A
Employees
15
N/A
Net Income
$12.73M
-5.0%
EBITDA
$13.15M
-8.5%
Quarterly Fundamentals
Net Cash
$178.76M
+83.5%
Accounts Receivable
$0.00
N/A
Inventory
$0.00
N/A
Long Term Debt
$0.00
N/A
Short Term Debt
$0.00
-100.0%
Return on Assets
-26.63%
N/A
Return on Invested Capital
-26.57%
N/A
Free Cash Flow
$7.97M
-49.1%
Operating Cash Flow
$7.52M
-40.6%